Class summary at a glance.

Every drug in the Vascular Endothelial Growth Factor Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 12tracked in Part D
CY24 Part D spend: $176.7Mcombined across class
Total Rx claims: 57K16K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Aflibercept

Brand: EYDENZELT · 43K Part D claims (CY24) · 13K beneficiaries · First FDA approval: 2011-11-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $111.8M

Class share

63%

of class CY24 spend

View profile →

Bevacizumab-Awwb

Brand: MVASI · 5K Part D claims (CY24) · 985 beneficiaries · First FDA approval: 2018-06-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $26.0M

Class share

15%

of class CY24 spend

View profile →

Bevacizumab-Bvzr

Brand: Zirabev · 3K Part D claims (CY24) · 721 beneficiaries · First FDA approval: 2020-01-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $15.6M

Class share

of class CY24 spend

View profile →

Bevacizumab

Brand: Avastin · 2K Part D claims (CY24) · 553 beneficiaries · First FDA approval: 2004-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $13.1M

Class share

of class CY24 spend

View profile →

Bevacizumab-Maly

Brand: ALYMSYS · 878 Part D claims (CY24) · 221 beneficiaries · First FDA approval: 2022-04-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $5.0M

Class share

of class CY24 spend

View profile →

Ranibizumab

Brand: LUCENTIS · 2K Part D claims (CY24) · 460 beneficiaries · First FDA approval: 2006-06-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.3M

Class share

of class CY24 spend

View profile →

Bevacizumab-Adcd

Brand: Vegzelma · 299 Part D claims (CY24) · 90 beneficiaries · First FDA approval: 2023-04-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $1.5M

Class share

of class CY24 spend

View profile →

Ranibizumab-Eqrn

Brand: CIMERLI · 139 Part D claims (CY24) · 40 beneficiaries · First FDA approval: 2022-10-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $223142

Class share

of class CY24 spend

View profile →

Ziv-Aflibercept

Brand: ZALTRAP · 13 Part D claims (CY24) · First FDA approval: 2012-08-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $68650

Class share

of class CY24 spend

View profile →

Ranibizumab-Nuna

Brand: Byooviz · 31 Part D claims (CY24) · First FDA approval: 2022-06-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $41974

Class share

of class CY24 spend

View profile →

Aflibercept-Ayyh

Brand: PAVBLU · — Part D claims (CY24) · First FDA approval: 2024-10-28

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Bevacizumab-Nwgd

Brand: JOBEVNE · — Part D claims (CY24) · First FDA approval: 2025-04-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.